Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

08 March 2012 Pursuing Your Dreams Despite a Serious Medical Condition

(Family Features) What would you do if you were frequently sick and knew that even catching a common cold could turn into a serious medical ordeal? This is a question that faces the approximately 250,000 people in the U.S. who have been diagnosed with primary immunodeficiency (PI).

> Read More
06 March 2012 CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms

CSL Behring announced today that treatment with Berinert®, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. While HAE patients treated within six hours of attack onset and those treated six hours or more after attack onset experienced a similar median time to onset of symptom relief, symptoms resolved considerably faster in patients who were treated earlier.

> Read More
04 March 2012 Analysis Finds Bioavailability of IgG Is Consistent, Regardless of Formulation

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route. The analysis, which was presented at the 2012 American Academy of Allergy, Asthma and Immunology annual meeting, was a joint effort between CSL Behring and physicians at University Hospital of Wales, Cardiff, UK and University of South Florida, St. Petersburg, USA.

> Read More
01 March 2012 CSL Behring Recognized As A "Pioneer" By European Organisation
For Rare Diseases (EURORDIS)

CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat congenital bleeding disorders, immune deficiencies, hereditary angioedema and inherited respiratory disease, is a subsidiary of CSL Limited (ASX:CSL).

> Read More
24 February 2012 First patient screened in CSL Behring global Phase I/III study of recombinant single-chain factor VIII

Vienna, Austria, 23 February, 2012— CSL Behring has announced that the first patient has been screened in its recombinant coagulation single-chain factor VIII (rFVIII) trial, part of the AFFINITY clinical trial program. The CSL Behring rFVIII, called ‘rVIII-SingleChain’, is a novel molecule being studied for the treatment of hemophilia A. It is being developed by CSL Behring, in collaboration with its parent company, CSL Limited (ASX:CSL).

> Read More
Page 25 of 51 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+